22 results
8-K
MIRA
Mira Pharmaceuticals Inc
19 Jul 24
Other Events
5:12pm
. In this report, such forward-looking statements relate to the anticipated benefits of the Company’s preclinical testing results for, and the time
8-K
MIRA
Mira Pharmaceuticals Inc
12 Jul 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
compliance with the Minimum Bid Requirement and (ii) the Company’s testing and potential benefits of MIRA-55. There can be no assurance
10-K
2023 FY
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
), and potentially PTSD. The strategy underscores patient safety while evaluating Ketamir-2’s therapeutic benefits and risks. The successful development … therapeutic benefits and risks.
Manufacture of Product for Pre-Clinical and Clinical Development Activities
Recipharm Israel LTD, a leading global
8-K
MIRA
Mira Pharmaceuticals Inc
7 Mar 24
Other Events
4:45pm
-looking statements include, without limitation, statements regarding the potential benefits of MIRA-55 versus MIRA1a, and the Company’s regulatory
8-K
EX-1.1
9bwe 6nkaaznlc
7 Aug 23
MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial
5:14pm
424B4
umixenjvzz52mg6z1
4 Aug 23
Prospectus supplement with pricing info
1:01pm
424B1
rafb7jkh tsan
4 Aug 23
Prospectus with pricing info
12:59pm
S-1
EX-10.11
pwjls
29 Jun 23
IPO registration
4:39pm
S-1
EX-99.3
it31i2b6xg bdsj73ww
29 Jun 23
IPO registration
4:39pm
S-1
vk12goqq6f 5yj
29 Jun 23
IPO registration
4:39pm
S-1
EX-10.1
po5oxl9s7v321la7qyg0
29 Jun 23
IPO registration
4:39pm
S-1
EX-14.1
jadcasydosnqnzr
29 Jun 23
IPO registration
4:39pm
DRS/A
EX-99.3
k1y89523149pa 29m
8 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
1l2337
8 Jun 23
Draft registration statement (amended)
12:00am